Elliott M Antman

List of Publications by Citations

149 papers	10,419 citations	38 h-index	102 g-index
165 ext. papers	12,293 ext. citations	11.3 avg, IF	5.96 L-index

#	Paper	IF	Citations
149	Edoxaban versus warfarin in patients with atrial fibrillation. *New England Journal of Medicine*, **2013**, 369, 2093-104	59.2	3215
148	TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. *Circulation*, **2000**, 102, 2031-7	16.7	1067
147	Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. *Circulation*, **2007**, 115, 1634-42	16.7	589
146	Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. *Lancet, The*, **2009**, 374, 989-997	40	531
145	Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). *American Heart Journal*, **2010**, 160, 635-41	4.9	377
144	Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. *Circulation*, **2001**, 103, 2550-4	16.7	366
143	Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. *Circulation*, **1996**, 94, 911-21	16.7	314
142	Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. *Lancet, The*, **2015**, 385, 2288-95	40	275
141	Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. *Journal of the American College of Cardiology*, **2008**, 51, 2028-33	15.1	269
140	Cyclooxygenase inhibition and cardiovascular risk. *Circulation*, **2005**, 112, 759-70	16.7	207
139	Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. *Circulation*, **2015**, 131, 82-90	16.7	202
138	Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. *Circulation*, **2002**, 105, 1642-9	16.7	190
137	Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. *Circulation*, **2016**, 134, 24-36	16.7	174
136	Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. *European Heart Journal*, **2014**, 35, 1457-65	9.5	130
135	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. *Lancet, The*, **2015**, 385, 2280-7	40	126
134	Precision medicine in cardiology. *Nature Reviews Cardiology*, **2016**, 13, 591-602	14.8	115
133	Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction: The OMEGA-REMODEL Randomized Clinical Trial. *Circulation*, **2016**, 134, 378-91	16.7	112

132	Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. *JACC: Heart Failure*, **2015**, 3, 180-8	7.9	105
131	Clinical Efficacy of Three Assays for Cardiac Troponin I for Risk Stratification in Acute Coronary Syndromes: A Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy. *Clinical Chemistry*, **2000**, 46, 453-460	5.5	102
130	Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. *Journal of the American College of Cardiology*, **2016**, 68, 1169-1178	15.1	99
129	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). *Circulation: Arrhythmia and Electrophysiology*, **2017**, 10,	6.4	94
128	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. *Circulation*, **2017**, 135, 1273-1275	16.7	94
127	Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. *Journal of the American College of Cardiology*, **2017**, 69, 1372-1382	15.1	87
126	Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. *Journal of the American Heart Association*, **2016**, 5,	6	79
125	The search for replacements for unfractionated heparin. *Circulation*, **2001**, 103, 2310-4	16.7	62
124	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). *Stroke*, **2016**, 47, 2075-82	6.7	57
123	Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data Registry. *JAMA Internal Medicine*, **2015**, 175, 207-15	11.5	56
122	Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. *Circulation*, **2019**, 139, 760-771	16.7	54
121	Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. *European Heart Journal*, **2019**, 40, 1541-1550	9.5	53
120	Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. *American Heart Journal*, **2002**, 143, 229-34	4.9	52
119	Pooling Data From Individual Clinical Trials in the COVID-19 Era. *JAMA - Journal of the American Medical Association*, **2020**, 324, 543-545	27.4	45
118	Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. *JAMA Cardiology*, **2016**, 1, 999-1006	16.2	45
117	Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. *Stroke*, **2014**, 45, 2372-8	6.7	43
116	Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation *European Heart Journal*, **2015**, 36, 1470-7	9.5	42
115	Pharmacoinvasive therapy: the future of treatment for ST-elevation myocardial infarction. *Circulation*, **2004**, 109, 2480-6	16.7	42

114	Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial. *Journal of the American Heart Association*, **2016**, 5,	6	42
113	Magnesium in acute MI. Timing is critical. *Circulation*, **1995**, 92, 2367-72	16.7	41
112	Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. *American Journal of Medicine*, **2016**, 129, 850-857.e2	2.4	40
111	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. *New England Journal of Medicine*, **2021**, 384, 1981-1990	59.2	37
110	Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. *Journal of the American College of Cardiology*, **2014**, 64, 576-84	15.1	35
109	Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine. *Wiley Interdisciplinary Reviews: Systems Biology and Medicine*, **2012**, 4, 367-83	6.6	34
108	Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. *European Heart Journal*, **2019**, 40, 1518-1527	9.5	34
107	Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). *JACC: Cardiovascular Interventions*, **2013**, 6, 1275-81	5	31
106	Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. *Journal of the American College of Cardiology*, **2019**, 74, 3013-3022	15.1	30
105	A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. *European Heart Journal*, **2017**, 38, 888-896	9.5	29
104	Transforming clinical trials in cardiovascular disease: mission critical for health and economic well-being. *JAMA - Journal of the American Medical Association*, **2012**, 308, 1743-4	27.4	28
103	Comprehensive characterization of protein-protein interactions perturbed by disease mutations. *Nature Genetics*, **2021**, 53, 342-353	36.3	27
102	Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial. *Journal of the American Heart Association*, **2017**, 6,	6	25
101	Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines. *American Heart Journal*, **2003**, 146, S18-22	4.9	23
100	Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. *Circulation* , **2018**, 138, 1963-1973	16.7	23
99	Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial. *American Heart Journal*, **2015**, 170, 1140-50	4.9	22
98	The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. *Journal of the American Society of Echocardiography*, **2016**, 29, 537-44	5.8	22
97	Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. *European Journal of Heart Failure*, **2019**, 21, 1571-1579	12.3	21

96	Evaluating the Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs. *Circulation*, **2017**, 135, 2062-2072	16.7	18
95	The role of cardiac troponin-I (cTnI) in risk stratification of patients with unstable coronary artery disease. *Clinical Cardiology*, **1999**, 22, 13-6	3.3	18
94	Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. *European Heart Journal*, **2018**, 39, 3810-3820	9.5	18
93	First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial. *International Journal of Cardiology*, **2017**, 244, 192-195	3.2	17
92	Atrial fibrillation and flutter: maintaining stability of sinus rhythm versus ventricular rate control. *Journal of Cardiovascular Electrophysiology*, **1995**, 6, 962-71	2.7	17
91	Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. *International Journal of Cardiology*, **2018**, 257, 102-107	3.2	14
90	Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial. *Journal of the American Heart Association*, **2017**, 6,	6	14
89	Should evidence-based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agents?. *Circulation*, **2003**, 108, 2604-7	16.7	14
88	A neural network system for detection of atrial fibrillation in ambulatory electrocardiograms. *Journal of Cardiovascular Electrophysiology*, **1994**, 5, 602-8	2.7	14
87	Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. *International Journal of Cardiology*, **2020**, 304, 185-191	3.2	13
86	Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. *American Heart Journal*, **2016**, 172, 144-51	4.9	13
85	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. *Journal of the American College of Cardiology*, **2020**, 75, 1095-1106	15.1	12
84	Pathogenesis and pathology of coronary heart disease syndromes. *Journal of Thrombosis and Thrombolysis*, **1999**, 8, 167-89	5.1	12
83	Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. *Thrombosis and Haemostasis*, **2018**, 118, 1001-1008	7	11
82	Nifedipine in the treatment of cardiovascular disease. *Pharmacotherapy*, **1981**, 1, 78-94	5.8	11
81	Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. *European Heart Journal*, **2021**, 42, 1698-1708	9.5	11
80	Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. *Journal of the American College of Cardiology*, **2021**, 77, 1197-1207	15.1	10
79	Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. *Circulation*, **2019**, 140, 1792-1801	16.7	8

78	The role of magnesium therapy in acute myocardial infarction. *Clinical Cardiology*, **1996**, 19, 841-4	3.3	8
77	Current diagnosis and prescription for Marfan syndrome: when to operate. *Journal of Cardiac Surgery*, **1994**, 9, 174-6	1.3	8
76	Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. *Thrombosis and Haemostasis*, **2021**, 121, 140-149	7	8
75	Edoxaban Versus Warfarin in Latin‐American Patients With Atrial‐Fibrillation: The ENGAGE AF-TIMI 48 Trial. *Journal of the American College of Cardiology*, **2018**, 72, 1466-1475	15.1	8
74	Clinical practice guidelines for chronic cardiovascular disorders: a roadmap for the future. *JAMA - Journal of the American Medical Association*, **2014**, 311, 1195-6	27.4	7
73	Pacemaker-mediated tachycardia initiated by coincident P-wave undersensing and ventricular blanking period. *PACE - Pacing and Clinical Electrophysiology*, **1985**, 8, 436-9	1.6	7
72	The Introduction and Clinical Use of Cardiac-Specific Troponin Assays. *Clinical Pharmacology and Therapeutics*, **2018**, 103, 31-33	6.1	6
71	Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. *Hypertension*, **2019**, 74, 597-605	8.5	6
70	Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma.. *JAMA Network Open*, **2022**, 5, e2147375	10.4	6
69	Clinical trials in cardiovascular medicine. *Circulation*, **2001**, 103, E101-4	16.7	5
68	Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58‐634 patients across four randomized controlled trials. *European Heart Journal - Cardiovascular Pharmacotherapy*, **2021**, 7, f40-f49	6.4	5
67	Genetic profiling of fatty acid desaturase polymorphisms identifies patients who may benefit from high-dose omega-3 fatty acids in cardiac remodeling after acute myocardial infarction-Post-hoc analysis from the OMEGA-REMODEL randomized controlled trial. *PLoS ONE*, **2019**, 14, e0222061	3.7	4
66	Evidence and education. *Circulation*, **2011**, 123, 681-5	16.7	4
65	ST-Elevation Myocardial Infarction46-90		4
64	Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis.. *JAMA Network Open*, **2022**, 5, e2147331	10.4	4
63	Data from Digital Health Devices Informs Ideal Cardiovascular Health. *Journal of Personalized Medicine*, **2021**, 11,	3.6	4
62	Sodium and Health: Old Myths and a Controversy Based on Denial.. *Current Nutrition Reports*, **2022**, 1	6	4
61	Clinical research and the development of medical therapeutics. *Circulation Journal*, **2014**, 78, 1267-71	2.9	3

60	Documented symptomatic bradycardia and symptom relief in patients receiving permanent pacemakers: an evaluation of the joint ACC/AHA pacing guidelines. *PACE - Pacing and Clinical Electrophysiology*, **1988**, 11, 1098-104	1.6	3
59	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. *Journal of Clinical Neuroscience*, **2021**, 86, 294-300	2.2	3
58	Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial. *Europace*, **2019**, 21, 306-312	3.9	3
57	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. *Circulation*, **2021**, 143, 685-695	16.7	3
56	Improving care at the population and individual level: lessons from SWEDEHEART. *European Heart Journal*, **2018**, 39, 3777-3779	9.5	3
55	NIH Centers for Accelerated Innovations Program: principles, practices, successes and challenges. *Nature Reviews Drug Discovery*, **2017**, 16, 663-664	64.1	2
54	Saving and Improving Lives in the Information Age: Presidential Address at the American Heart Association 2014 Scientific Sessions. *Circulation*, **2015**, 131, 2238-42	16.7	2
53	Clinical Trials and Response to CRT130-155		2
52	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. *Circulation*, **2021**, 143, 673-684	16.7	2
51	Response to Letter Regarding Article, Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. *Circulation*, **2010**, 122	16.7	1
50	Programming CRT Devices180-219		1
49	The specialty of emergency medicine: needed now more than ever before. *Annals of Emergency Medicine*, **2008**, 52, 317-9	2.1	1
48	Inside the FDA: The Business and Politics Behind the Drugs We Take and the Food We Eat. *Circulation*, **2005**, 112,	16.7	1
47	The inclusion of augmented intelligence in medicine: A framework for successful implementation.. *Cell Reports Medicine*, **2022**, 3, 100485	18	1
46	Digital health device measured sleep duration and ideal cardiovascular health: an observational study. *BMC Cardiovascular Disorders*, **2021**, 21, 497	2.3	1
45	A Biomarker-Centric Approach to Drug Discovery and Development: Lessons Learned from the Coronavirus Disease 2019 Pandemic. *Journal of Pharmacology and Experimental Therapeutics*, **2021**, 376, 12-20	4.7	1
44	Ideal Cardiovascular Health in Young Adults With Established Cardiovascular Diseases.. *Frontiers in Cardiovascular Medicine*, **2022**, 9, 814610	5.4	1
43	Exploring patient experiences coping with using multiple medications: a qualitative interview study. *BMJ Open*, **2021**, 11, e046860	3	0

42	Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study. *American Heart Journal*, **2021**, 235, 132-139	4.9	0
41	A precision medicine approach to sex-based differences in ideal cardiovascular health. *Scientific Reports*, **2021**, 11, 14848	4.9	0
40	Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups. *International Journal of Cardiology*, **2020**, 317, 159-166	3.2	0
39	Reducing the risk of heart attack and stroke: the American Heart Association/American College of Cardiology prevention guidelines. *Circulation*, **2014**, 130, e48-50	16.7	
38	Reexamination of the Thrombin Hypothesis: What We Have Learned from TIMI 9B and GUSTO IIb. *Journal of Thrombosis and Thrombolysis*, **1997**, 4, 321-323	5.1	
37	Long-Term Pharmacologic Management of Atrial Fibrillation for Control of Rate and Rhythm. *Journal of Interventional Cardiac Electrophysiology*, **1997**, 1, 40-43		
36	Pharmacological Therapy of Cardiac Arrhythmias. *Journal of Thrombosis and Thrombolysis*, **1998**, 6, 211-238	5.1	
35	The Thrombin Hypothesis: Dead or Alive?. *Journal of Thrombosis and Thrombolysis*, **1998**, 5, S137-S141	5.1	
34	Noninvasive Cardiac Imaging in Chest Pain Syndromes. *Journal of Thrombosis and Thrombolysis*, **1998**, 6, 239-252	5.1	
33	Antiplatelet Therapy in Peripheral Arterial Disease196-214		
32	Laboratory Assessment of Platelet Function and the Effects of Antiplatelet Agents15-29		
31	Author Disclosure Table291-296		
30	Platelet Physiology and the Role of the Platelet in Ischemic Heart Disease1-14		
29	Antiplatelet Therapy in Acute Coronary Syndrome without ST Elevation143-163		
28	Antiplatelet Therapy in ST-Elevation Myocardial Infarction164-177		
27	Antiplatelet Therapy in Chronic Coronary Artery Disease178-195		
26	Clinical use of Antiplatelet Agents in Cardiovascular Disease: Cerebrovascular Diseases215-229		
25	Antiplatelet Therapy and Coronary Bypass Surgery: Risks and Benefits231-250		

6	Mechanical Assessment of the Failing Heart92-129	
5	The Long-term Pharmacologic Management of Atrial Fibrillation for Control of Rate and Rhythm. *Journal of Interventional Cardiac Electrophysiology*, **1999**, 3, 96-99	
4	Non-CRT Pacing in the Failing Heart: Limiting Ventricular Pacing and Searching for Alternate Pacing Sites248-283	
3	Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. *Annals of Internal Medicine*, **1999**, 131, 235	8
2	Obesity and Ideal Cardiovascular Health: Results from the My Research Legacy Study. *Obesities*, **2021**, 1, 36-48	
1	An overview of the process, progress, and outcomes of a National Center for Accelerated Innovation: The Boston Biomedical Innovation Center Experience. *Journal of Clinical and Translational Science*, **2021**, 5, e137	0.4